


J0829

READING
ROOM



Journal of Pharmaceutical Sciences

A publication of the American Pharmaceutical Association



SEPTEMBER 1970

VOLUME 59 NUMBER 9

Coden: JPMSA

Journal of Pharmaceutical Sciences



SEPTEMBER 1970
VOLUME 59 NUMBER 9

EDWARD G. FELDMANN
Editor

MARY HUDSON FERGUSON
Associate Editor

SHELLY ELLIOTT
Production Editor

L. LUAN CORRIGAN
Contributing Editor

SAMUEL W. GOLDSTEIN
Contributing Editor

LINDA A. LAFONTAINE
Contributing Editor

EDITORIAL ADVISORY BOARD

JACK COOPER

W. LEWIS NOBLES

EDWARD R. GARRETT

G. VICTOR ROSSI

GERHARD LEVY

GORDON H. SVOBODA

COMMITTEE ON PUBLICATIONS

ROBERT C. JOHNSON,
Chairman

GROVER C. BOWLES, JR.

CLIFTON J. LATIOLAIS

WILLIAM S. APPLE

JOHN H. NEUMANN

The *Journal of Pharmaceutical Sciences* is published monthly by the American Pharmaceutical Association at 20th & Northampton Sts., Easton, PA 18042. Second-class postage paid at Easton, Pa., and at additional mailing offices.

All expressions of opinion and statements of supposed fact appearing in articles or editorials carried in this journal are published on the authority of the writer over whose name they appear and are not to be regarded as necessarily expressing the policies or views of the American Pharmaceutical Association.

Offices—Editorial, Advertising, and Subscription Offices: 2215 Constitution Ave., N. W., Washington, DC 20037. Publication Offices: 20th & Northampton Streets, Easton, PA 18042.

Annual Subscriptions—United States and foreign, industrial and government institutions \$50, educational institutions \$30, individuals for *personal use only* \$20; single copies \$3. Subscription rates are subject to change without notice. Members of the American Pharmaceutical Association may elect to receive the *Journal of Pharmaceutical Sciences* as a part of their annual \$40 APHA membership dues.

Claims—Missing numbers will not be supplied if dues or subscriptions are in arrears for more than 60 days, or if claims are received more than 60 days after the date of the issue, or if loss was due to failure to give notice of change of address. The Association cannot accept responsibility for foreign delivery when its records indicate shipment has been made.

Change of Address—Members and subscribers should notify at once both the Post Office and the American Pharmaceutical Association, 2215 Constitution Ave., N. W., Washington, DC 20037, of any change of address. © Copyright 1970, American Pharmaceutical Association, 2215 Constitution Ave., N. W., Washington, DC 20037.

ADVANCING THE CAUSE OF THERAPEUTIC ORPHANS

The problems associated with prescribing drugs for children were discussed previously on this page (*see June 1968*, "Therapeutic Orphans"). While knowledge concerning the actions and mechanisms of drugs is slowly unraveling, only a relatively few steps have been taken in a process that ultimately will require much study and research for a full understanding.

Determining drug actions and mechanisms in children is often complicated by different rates of metabolism, partially developed enzyme systems, and other factors associated with growth and maturation which are difficult to characterize and control under experimental conditions. In addition, for drugs not developed specifically for children and possibly having limited use in that age group, industry often may consider the expense of determining dosages and effects in children difficult to justify. Moreover, the legal problems and social ramifications involved with using children and infants in clinical trials further complicate the development of suitable criteria for children's doses.

Nevertheless, drugs *are* and *must* be used for children. Therefore, the most up-to-date information available is needed in a form that is easily used. For these reasons, the *1971 Pediatric Dosage Handbook: Usual Doses for Infants and Children* has been compiled by Dr. Harry C. Shirkey and published by the American Pharmaceutical Association.

The reliability or credibility of a reference source of this nature is associated primarily with the individuals and organizations involved with its compilation and publication. Dr. Shirkey, who earned his pharmacy and medical degrees from the University of Cincinnati, has practiced as a pediatrician since 1948; currently, he serves on the staff of several hospitals and also as a medical school faculty member, teaching courses in both pharmacology and pediatrics.

In addition, Dr. Shirkey serves as a member of the NF Board and Chairman of the NF Committee on Admissions. He is also Chairman of the Pediatric Panel of the USP and is a member of the Revision Committee. His American Medical Association activities include chairing the Drug Utilization Committee and serving as Vice-Chairman of the Council on Drugs.

The major feature of the *Handbook* is the comprehensive "Table of Pediatric Drugs, Their Dosage, Cautions and Contraindications for Use, and Their Available Dosage Forms." The material in this table reflects the most current and accurate information available concerning dosages for children and infants specifically.

While the need persists for more breadth and depth in research designed to elucidate drug mechanisms in adults as well as children, the publication of the *Pediatric Dosage Handbook* helps bridge the gap between research and practice as well as between research and consumer. Hopefully, this *Handbook* will aid in the effective and safe use of drugs with children and make them less "therapeutic orphans" and more like "foster children" at least.

Edward G. Feldmann

Journal of Pharmaceutical Sciences



SEPTEMBER 1970
VOLUME 59 NUMBER 9

EDITORIAL

Advancing the Cause of Therapeutic Orphans

REVIEW ARTICLE

- 1205 P. N. Patil, J. B. LaPidos, A. Tye
Steric Aspects of Adrenergic Drugs

RESEARCH ARTICLES

- 1234 Wen-Hung Wu, Ting-Fong Chin, John L. Lach
Interaction of Isoniazid with Magnesium Oxide and Lactose
- 1243 Donald E. Cadwallader, Janis R. Phillips
Behavior of Erythrocytes in Various Solvent Systems VI: Water-Tetramethylurea
- 1246 Harold L. Newmark, Julius Berger
Coumermycin A₁—Biopharmaceutical Studies I
- 1249 Harold L. Newmark, Julius Berger, J. Thurø Carstensen
Coumermycin A₁—Biopharmaceutical Studies II
- 1252 M. David MacFarlane, Theodore Koppanyi
Acetylcholine Tachyphylaxis in Isolated Rabbit Atrium and Its Relation to Norepinephrine Stores
- 1255 John W. Poole
Effect of Sex on Penicillin Blood Levels in Dogs
- 1258 Robert A. O'Reilly, Gerhard Levy
Pharmacokinetic Analysis of Potentiating Effect of Phenylbutazone on Anticoagulant Action of Warfarin in Man
- 1261 John L. Lach, Lyle D. Bighley
Diffuse Reflectance Studies of Solid-Solid Interactions
- 1265 John W. Poole, C. Kanta Bahal
Dissolution Behavior and Solubility of Anhydrous and Dihydrate Forms of Wy-4508, an Aminoalicyclic Penicillin
- 1267 Harald G. O. Holck, Paul M. Lish, David W. Sjogren, W. W. Westerfeld, Marvin H. Malone
Effects of Disulfiram on Growth, Longevity, and Reproduction of the Albino Rat
- 1271 Jordan L. Cohen, Kenneth A. Connors
Stability and Structure of Some Organic Molecular Complexes in Aqueous Solution
- 1276 Gerald J. Kelliher, Joseph P. Buckley
Central Hypotensive Activity of *dl*- and *d*-Propranolol
- 1281 K. S. Murthy, George Zografi
Oil-Water Partitioning of Chlorpromazine and Other Phenothiazine Derivatives Using Dodecane and *n*-Octanol
- 1286 J. David McCallister, Ting-Fong Chin, John L. Lach
Diffuse Reflectance Studies of Solid-Solid Interactions IV: Interaction of Bishydroxycoumarin, Furosemide, and Other Medicinal Agents with Various Adjuvants
- 1290 Louis J. Ravin, Elie G. Shami, Elisabeth Rattie
Physical-Chemical Evaluation of 3-(3-Hydroxy-3-methylbutylamino)-5-methyl-*as*, Triazino [5,6-*b*] Indole (SK & F 30097)
- 1295 Ian H. Pitman, Mark A. Ziser
Thermodynamics and Kinetics of Covalent Addition of Bisulfite Ion to Pyrimidinium Ions
- 1300 Ping-Hong Chung, Ting-Fong Chin, John L. Lach
Kinetics of the Hydrolysis of Pilocarpine in Aqueous Solution
- 1306 T. L. Breon, A. N. Paruta
Solubility Profiles for Several Barbiturates in Hydroalcoholic Mixtures
- 1313 Yvonne C. Martin, Ronald G. Wiegand
Metabolism and Excretion of Chromonar and Its Metabolite in Dog and Man

Contents continued from outside back cover

DRUG STANDARDS

- 1319 **Ivo Setnikar, Febo Fontani**
Content Uniformity in Rectal Suppositories
- 1324 **Lee T. Grady, Rupert O. Zimmerer, Jr.**
USP Collaborative Study of the Assay of Atropine and Scopolamine Dosage Forms
- 1328 **Harris I. Tarlin, Martin Batchelder**
Determination of Total Iron in Hematinics by Atomic Absorption Spectrophotometry
- 1331 **M. S. Karawya, M. G. Ghourab**
Assay of Chloramphenicol and Its Esters in Formulations
- 1333 **M. J. Cho, M. Pernarowski**
Application of Absorbance Ratios to Analysis of Pharmaceuticals VI: Analysis of Binary Mixture Using a Reference Spectrum

TECHNICAL ARTICLES

- 1336 **N. L. Henderson, A. J. Bruno**
Lactose USP (Beadlets) and Dextrose (PAF 2011): Two New Agents for Direct Compression
- 1341 **Tsuneto Kuriyama, Michiharu Nobutoki, Michio Nakanishi**
Permeability of Double-Layer Films I

NOTES

- 1344 **Tsuneto Kuriyama, Michiharu Nobutoki, Michio Nakanishi**
Permeability of Double-Layer Films II
- 1346 **William R. Maynard, Jr., Robert B. Bruce**
GLC Determination of Guaiacol Glyceryl Ether in Blood
- 1348 **William O. Foye, James Mickles, Gerard M. Boyce**
Antiradiation Compounds XIV: Dithiocarbamates of Aminothiophenes
- 1350 **F. I. Carroll, Monroe E. Wall**
N-Substituted Aminoethanethiols and *N*-Substituted Aminoethanethiol *S*-Sulfonic Acids as Radioprotective Agents
- 1353 **Werner Lowenthal, Joseph F. Borzelleca, Charles D. Corder, Jr.**
Drug Absorption from the Rectum III: Aspirin and Some Aspirin Derivatives

COMMUNICATIONS

- 1356 **Robert E. Harmon, S. K. Gupta, J. L. Hansen, L. J. Hanka**
Preparation and Biological Activity of Substituted 1,3-Distyryl-4,6-dinitrobenzenes
- 1357 **Richard J. Warren, R. John Stedman, Elie G. Shami, Elisabeth S. Rattic, Louis J. Ravin**
Observations on the Micelle Formation of 2-Butyl-3-benzofuranyl-4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl Ketone Hydrochloride (SK & F 33134-A) by NMR Spectroscopy
- 1358 **Y. Fulmer Shealy, C. Allen O'Dell**
Imidazole and Pyrazole Bis(2-fluoroethyl)triazenes
- 1360 **B. A. Matthews, C. T. Rhodes**
Aggregation Mechanisms in Pharmaceutical Suspensions
- 1362 **Devendra K. Madan, Donald E. Cadwallader**
Effect of Macromolecules on Aqueous Solubility of Cholesterol
- 1364 **J. C. Stone**
Objective Visual Evaluation of the Relative Content of Major and Minor Defects in Tablets and Capsules

- 1365 **BOOKS**

Objective Visual Evaluation of the Relative Content of Major and Minor Defects in Tablets and Capsules

Keyphrases Tablets, capsules—relative defect determination
 Defects, tablets and capsules—visual determination method

Sir:

Recently, it became desirable for our Quality Control Department to develop and subsequently implement a reasonably objective analysis for the evaluation of major and minor physical defects in tablets and capsules. The results would then be used to determine if additional processing was required prior to packaging.

Even though major and minor physical defects are routinely monitored by most pharmaceutical manufacturers, we were unable to find a reference regarding a test method in the literature. Consequently, a visual method has been developed which allows for the monitoring of major and minor physical defects in tablets and capsules.

Basically, the method consists of filling a rectangular plastic (Plexiglas) tray, a monolayer in depth, with the test tablets or capsules. The tray is placed on a workbench and positioned under a lamp containing a 100-watt incandescent lightbulb. The tray's width is placed parallel to the front bench edge about 7.62–15.24 cm. (3–6 in.) from the edge. The lamp is connected to a timer¹ that activates illumination of the lightbulb for a required amount of time.

Table I—Definition of Major and Minor Defects

Major Defects	Minor Defects
Surface spots	Polishing not uniform
Breaks or cracks	Feathered edges
Coated base tablet exposed	Chips
Foreign particulate matter ^a	Pitting or pimples
	Atypical mottling
	Nonuniform color
	Nonuniform size or shape
	Not smooth
	Smeared printing
	Thin-coated edges

^a Detection of this major defect results in rejection of the lot until it is freed of any health hazard resulting from this defect.

Subsequently, the start button of the timer is depressed and the tablets are scanned for both major and minor defects (Table I); the defective tablets are marked, using a felt-tipped pen (or equivalent). Automatically, the light is turned off, signifying the end of the analysis. The number and types of defects are sorted, and the results are recorded on an assay report

form. The report is designed so that the number and types of defects are identified.

An empty tray is superimposed over the tablet-containing tray, and the two trays are rotated 180° around the *x*- or *y*-axis so that the reverse side of the tablets are exposed. The original tray is removed, and the assay is performed on the new exposed side of the samples. The procedure is repeated until the total number of tablets or capsules required in the evaluation is assayed, and the results are recorded accumulatively.

The total number of units assayed is related to batch size and based on Military Standard 105D. Using the average tablet or capsule weight, the number of units to be tested are weighed into a beaker for subsequent transfer to the testing tray. A double sampling plan is used in which the acceptable quality level (A. Q. L.) is 0.65 and 4.0%, respectively, for major and minor defects.

Two sets of trays (two identical trays per set) are required to accommodate capsules, capsule-shaped tablets, and the conventional standard-shaped tablets. All the trays are 22.86 × 15.24 cm. (9 × 6 in.); however, the trays used for capsules and capsule-shaped tablets have an inner depth of 0.32 cm. (0.125 in.), and the trays used for the standard-shaped tablets have an inner depth of 0.16 cm. (0.062 in.).

Since the size of the tablet or capsule being assayed dictates the number of units in each tray load, the time interval (length of time light is illuminated) is correspondingly adjusted. In effect, the illumination duration is longest for the smallest tablet assayed. After a year of using this technique, we have developed the following formula for determining the time interval for a given sample:

$$P \text{ seconds/tablet} \times \frac{\text{total number of tablets to be assayed}}{\text{number of filled trays}} = \text{seconds/tray (Eq. 1)}$$

The value of *P* chosen should reflect the desired rigidity of the inspection. In our laboratory, *P* has an average value of 0.035 sec./tablet. If 1000 tablets were to be tested and five filled trays were involved, the time interval would be 7 sec./tray. If the last tray is less than half a tray, half the time interval is used. Otherwise, the tray is considered a full tray.

We found that the number of tablets scanned per tray varies between analysts, and the formula attempts to compromise these differences. Otherwise, the natural tendency of the analyst is to become overcritical of the sample appearance.

J. C. STONE
 Quality Control Laboratories
 Warren-Teed Pharmaceuticals Inc.
 Columbus, OH 43215

Received April 13, 1970.

Accepted for publication May 27, 1970.

The author thanks Mr. Frank Blackett for his advice and counsel during the assemblment of the testing equipment, and the invaluable assistance provided by the Quality Control Department.

¹ Model M-1M, Industrial Timer Corporation, Parsippany, N. J.